US 2010/0145023 A1 · Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins

Abstract

An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.

Claims12

Dependent claims

An isolated nucleic acid molecule selected from the group consisting of:

the VH region shown in SEQ ID NO:11 (FIG. 6);
the CH region shown in SEQ ID NO:13 (FIG. 6);
the VL region shown in SEQ ID NO:15 (FIG. 6);
the CL region shown in SEQ ID NO:17 (FIG. 6);
the heavy chain sequence with RBS and leader region shown in SEQ ID NO:5 (FIG. 3);
the light chain sequence with RBS and leader shown in SEQ ID NO:7 (FIG. 4);
the bouganin sequence with RBS and leader shown in SEQ ID NO:9 (FIG. 5);
the bouganin sequence shown in SEQ ID NO:19 (FIG. 6);
the VB6-845 sequence shown in SEQ ID NO:3 (FIG. 2);
the first PelB leader sequence and initial sequence including histidines optimized shown in SEQ ID NO:21 (FIG. 6);
the second PelB leader sequence and intervening sequence shown in SEQ ID NO:23 (FIG. 6);
and
the furin linker sequence shown in SEQ ID NO:25 (FIG. 6).

10 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/596,188Filed 18 Apr 2008

Priority

19 Apr 2007

Published

10 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61P 35/00
Antineoplastic agents

Abstract

Claims12

Dependent claims

An isolated nucleic acid molecule selected from the group consisting of:

the VH region shown in SEQ ID NO:11 (FIG. 6);
the CH region shown in SEQ ID NO:13 (FIG. 6);
the VL region shown in SEQ ID NO:15 (FIG. 6);
the CL region shown in SEQ ID NO:17 (FIG. 6);
the heavy chain sequence with RBS and leader region shown in SEQ ID NO:5 (FIG. 3);
the light chain sequence with RBS and leader shown in SEQ ID NO:7 (FIG. 4);
the bouganin sequence with RBS and leader shown in SEQ ID NO:9 (FIG. 5);
the bouganin sequence shown in SEQ ID NO:19 (FIG. 6);
the VB6-845 sequence shown in SEQ ID NO:3 (FIG. 2);
the first PelB leader sequence and initial sequence including histidines optimized shown in SEQ ID NO:21 (FIG. 6);
the second PelB leader sequence and intervening sequence shown in SEQ ID NO:23 (FIG. 6);
and
the furin linker sequence shown in SEQ ID NO:25 (FIG. 6).

10 more elements

Dependencies are inferred from the claim text.

Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins

Life of this patent

Abstract

Claims12

Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins

Life of this patent

Abstract

Claims12